These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27406378)

  • 1. Treat to target in systemic lupus erythematosus: a commentary.
    Ugarte-Gil MF; Burgos PI; Alarcón GS
    Clin Rheumatol; 2016 Aug; 35(8):1903-1907. PubMed ID: 27406378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort.
    Alarcón GS; Ugarte-Gil MF; Pons-Estel G; Vilá LM; Reveille JD; McGwin G
    Lupus; 2019 Mar; 28(3):423-426. PubMed ID: 30678605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treat to target in systemic lupus erythematosus].
    Mucke J; Düsing C; Chehab G; Schneider M
    Z Rheumatol; 2020 May; 79(4):351-358. PubMed ID: 32232548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Quintana R; Gómez-Puerta JA; Catoggio LJ; Alvarellos A; Saurit V; Borba E; Sato E; Costallat L; Da Silva NA; Iglesias-Gamarra A; Neira O; Reyes-Llerena G; Cardiel MH; Amigo MC; Acevedo-Vásquez E; Esteva-Spinetti MH; Alarcón GS; Pons-Estel BA
    J Rheumatol; 2019 Oct; 46(10):1299-1308. PubMed ID: 30824636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Better Health-Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cárdenas RV; Reátegui-Sokolova C; Medina-Chinchón M; Zevallos F; Elera-Fitzcarrald C; Pimentel-Quiroz V; Cucho-Venegas JM; Rodríguez-Bellido Z; Pastor-Asurza CA; Alarcón GS; Perich-Campos R
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1159-1162. PubMed ID: 31199590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
    van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
    Ann Rheum Dis; 2017 Mar; 76(3):554-561. PubMed ID: 27884822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 10. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treat to target, remission and low disease activity in SLE.
    Morand EF; Mosca M
    Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):342-350. PubMed ID: 29224676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort.
    Ugarte-Gil MF; Pons-Estel GJ; Vila LM; McGwin G; Alarcón GS
    RMD Open; 2019; 5(1):e000955. PubMed ID: 31245057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
    Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treat-to-target in systemic lupus erythematosus: are we there yet?
    Mok CC
    Expert Rev Clin Pharmacol; 2016; 9(5):675-80. PubMed ID: 26809011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuropsychiatric Systemic Lupus Erythematosus].
    Tanaka Y
    Brain Nerve; 2016 Sep; 68(9):1035-1048. PubMed ID: 27667489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treat-to-target in systemic lupus erythematosus: Where are we?
    Ríos-Garcés R; Espinosa G; van Vollenhoven R; Cervera R
    Eur J Intern Med; 2020 Apr; 74():29-34. PubMed ID: 32014364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.
    Jesus D; Larosa M; Henriques C; Matos A; Zen M; Tomé P; Alves V; Costa N; Le Guern V; Iaccarino L; Costedoat-Chalumeau N; Doria A; Inês LS
    Ann Rheum Dis; 2021 Dec; 80(12):1568-1574. PubMed ID: 34407927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged remission in systemic lupus erythematosus.
    Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
    J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active implementation of low disease activity state as a treatment endpoint in childhood-onset systemic lupus erythematosus in routine practice is both feasible and associated with better outcomes.
    Gotch R; Ahmed Y; Wilson R; Hawkins E; Ciurtin C
    Clin Rheumatol; 2024 Oct; 43(10):3231-3238. PubMed ID: 39212796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.